Multiple myeloma (MM) is one of the haematological malignancies with the fastest therapeutic development. Consequently, interesting new data on both preclinical and clinical progress in MM were presented at the 2016 EHA meeting in Copenhagen. We have selected four clinical and one preclinical abstract for discussion in this paper. The choice is based on the importance of the presentations and the impact their results will have on the future treatment landscape in MM.

(BELG J HEMATOL 2016;7(4):130–3)